About Werewolf Therapeutics
Werewolf Therapeutics is developing a new class of cancer treatments designed to stay inactive until they reach the tumor—helping the medicine work harder where it’s needed most and reducing side effects elsewhere. Powered by our investigational INDUKINE™ molecules, this approach is designed to activate the body’s own immune system to fight cancer, even in hard-to-treat
or treatment-resistant tumors. We call it the “Full Moon Moment,” not just for how the science works, but for what it represents for patients: a turning point when possibility returns. As our therapies continue to be studied, we hope to create more “Full Moon Moments” with the potential to change the lives of patients with cancer. Clinical Trials
Werewolf Therapeutics is currently enrolling two clinical trials testing innovative treatments designed to activate the body’s own immune system to fight cancer.
• WTX-124, is designed to harness the IL-2 cytokine to directly stimulate cancer-fighting immune cells within the tumor microenvironment, focusing on cancers like cutaneous melanoma, cutaneous squamous cell carcinoma, renal cell carcinoma, and non-small cell lung cancer.
• WTX-330, is designed to employ IL-12 to activate a wide range of immune cells to trigger a broad and rapid immune response against the cancer, targeting cancers such as metastatic cutaneous melanoma that doesn’t respond to checkpoint inhibitors, microsatellite-stable colorectal cancer, and relapsed or refractory non-Hodgkin lymphoma. To learn more about these ongoing clinical trials, please visit https://werewolftx.com/clinical-trials/ or contact [email protected].
